PHAT Phathom Pharmaceuticals, Inc. - Common Stock
NASDAQ · Pharmaceuticals · Auf SEC EDGAR ansehen ↗ Schließen Okt 2, 2026 10-K/10-Q Jul 30, 2026
$6,92
· % der 52-Wochen-Spanne
· über Tiefststand
· zu hoch
$6,8252-Wochen-Tief
$18,3152-Wochen-Hoch
Marktkapitalisierung (MRQ)
$554M
P/E (TTM)
-5.5
EPS (TTM)
$-1.25
Umsatz (TTM)
$240M
Ihre Abzeichen
52W-Spanne
$7–$18
Analystenbewertung
BUY
Kursziel
$20
P/E
-5.5
ROE
26.4%
Nettogewinnmarge
-41.3%
Ihre Abzeichenleiste ist leer – heften Sie eine Kennzahl auf dieser Seite an.
PHAT Aktien-Snapshot Kurs, Marktkapitalisierung, P/E, EPS, ROE, Schulden/Eigenkapital, 52-Wochen-Spanne
Kurs
$6.92
Marktkapitalisierung (MRQ)
$554M
P/E (TTM)
-5.5
EPS (TTM)
$-1.25
Umsatz (TTM)
$240M
ROE (TTM)
26.4%
Verschuldungsgrad (MRQ)
-0.5
52W-Spanne
$7–$18
PHAT Aktienkurs-Chart Täglich OHLCV mit technischen Indikatoren — Schwenken, Zoom und Ansicht anpassen
Spanne
Balken
Die Balkengranularität passt sich der ausgewählten Periode an – bewegen Sie den Mauszeiger über das Diagramm, um Eröffnungs-/Höchst-/Tiefst-/Schlusskurse für einen Balken anzuzeigen.
10-Jahres-Performance Umsatz-, Nettoergebnis-, Margen- und EPS-Trends
Umsatz$175M2022-12-31 → 2025-12-31
EPS$-3.032021-12-31 → 2025-12-31
Freier Cashflow$-167M2019-12-31 → 2025-12-31
Nettogewinnmarge-41.3%2023-12-31 → 2025-12-31
Bewertung & Kennzahlen
Bewertung P/E-, P/S-, P/B-, EV/EBITDA-Verhältnisse — ist die Aktie teuer oder günstig?
| Kennzahl | 5-Jahres-Trend | PHAT | 5-Jahres-Durchschnitt | Peer-Median | Fazit |
|---|---|---|---|---|---|
| P/E (TTM) | -5.55-Jahres-Durchschnitt ≈-3.3 | ≈-3.3 | · | · | |
| P/S (TTM) | 2.35-Jahres-Durchschnitt ≈263.8 | ≈263.8 | 2.7 | Teurer | |
| K/B (MRQ) | -1.65-Jahres-Durchschnitt ≈-1.9 | ≈-1.9 | · | · | |
| EV / EBITDA | -3.95-Jahres-Durchschnitt ≈-3.4 | ≈-3.4 | · | · | |
| Kurs / FCF (TTM) | -15.05-Jahres-Durchschnitt ≈-4.0 | ≈-4.0 | · | · | |
| Kurs / Cashflow (TTM) | -15.15-Jahres-Durchschnitt ≈-4.0 | ≈-4.0 | · | · | |
| EV / Revenue (EV / Umsatz) | 3.65-Jahres-Durchschnitt ≈144.3 | ≈144.3 | · | · | |
| EV / FCF | -3.85-Jahres-Durchschnitt ≈-3.4 | ≈-3.4 | · | · |
Der Median der Vergleichsgruppe wird pro Kennzahl standardisiert berechnet und stimmt möglicherweise nicht immer mit der für diese Aktie angezeigten TTM/MRQ-Basis überein.
Rentabilität Brutto-, Betriebs- und Nettomargen; ROE, ROA, ROIC
| Kennzahl | 5-Jahres-Trend | PHAT | 5-Jahres-Durchschnitt | Peer-Median | Fazit |
|---|---|---|---|---|---|
| Bruttogewinnmarge (TTM) | 82.9%5-Jahres-Durchschnitt ≈82.7% | ≈82.7% | 71.8% | Spitzenklasse | |
| Betriebsgewinnmarge (TTM) | -17.0%5-Jahres-Durchschnitt ≈-8375.4% | ≈-8375.4% | -1.8% | Unterdurchschnittlich | |
| EBITDA-Marge (TTM) | -16.7%5-Jahres-Durchschnitt ≈-8346.7% | ≈-8346.7% | 1.8% | Schwach | |
| Pretax Margin (Vorgewinnmarge) | -126.4% | · | -6.8% | Schwach | |
| Nettogewinnmarge (TTM) | -41.3%5-Jahres-Durchschnitt ≈-10096.8% | ≈-10096.8% | -7.5% | Schwach | |
| ROA (TTM) | -34.3%5-Jahres-Durchschnitt ≈-78.9% | ≈-78.9% | -15.7% | Schwach | |
| ROE (TTM) | 26.4%5-Jahres-Durchschnitt ≈175.3% | ≈175.3% | 52.3% | Im Einklang | |
| ROIC | 69.8% | · | 40.3% | Spitzenklasse |
Finanzielle Gesundheit Verschuldung, Liquidität, Solvenz — Bilanzstärke
| Kennzahl | 5-Jahres-Trend | PHAT | 5-Jahres-Durchschnitt | Peer-Median | Fazit |
|---|---|---|---|---|---|
| Fremdkapital / Eigenkapital (MRQ) | -0.55-Jahres-Durchschnitt ≈-0.6 | ≈-0.6 | 0.0 | Geringe Verschuldung | |
| Liquiditätsgrad (MRQ) | 1.95-Jahres-Durchschnitt ≈6.4 | ≈6.4 | 3.0 | Geringe Liquidität | |
| Quick Ratio | 1.65-Jahres-Durchschnitt ≈6.2 | ≈6.2 | 2.0 | Im Einklang | |
| Langfristige Schulden / Eigenkapital (MRQ) | -0.55-Jahres-Durchschnitt ≈-0.6 | ≈-0.6 | 0.0 | Geringe Verschuldung |
Wachstum Umsatz-, EPS- und Nettoergebniswachstum: YoY, 3-Jahres-CAGR, 5-Jahres-CAGR
| Kennzahl | 5-Jahres-Trend | PHAT | 5-Jahres-Durchschnitt | Peer-Median | Fazit |
|---|---|---|---|---|---|
| Revenue YoY (Umsatz YoY) | 216.9% | · | · | · |
Kapitaleffizienz Umsatz pro Vermögenswert, Lagerumschlag, Forderungsumschlag
| Kennzahl | 5-Jahres-Trend | PHAT | 5-Jahres-Durchschnitt | Peer-Median | Fazit |
|---|---|---|---|---|---|
| Asset Turnover (Umsatz / Vermögenswerte) | 0.55-Jahres-Durchschnitt ≈0.2 | ≈0.2 | 0.5 | Spitzenklasse | |
| Inventory Turnover (Lagerumschlag) | 5.25-Jahres-Durchschnitt ≈3.0 | ≈3.0 | 3.0 | Spitzenklasse | |
| Receivables Turnover (Forderungsumschlag) | 3.05-Jahres-Durchschnitt ≈2.2 | ≈2.2 | 3.5 | Schwach | |
| Revenue / Employee (Umsatz / Mitarbeiter) | ≈$472.0K | · | · | · |
Wert · ≈ 5-Jahres-Durchschnitt · Branchenmedian · Urteil relativ zum Median
Ergebnisverlauf EPS Ist vs. Schätzung, Überraschung %, Beat-Rate, nächstes Ergebnisdatum
Durchschn. Überraschung
7.7%
Nächster Bericht
Okt 28, 2026
| Zeitraum | Bericht | EPS Actual | EPS est. | Überraschung |
|---|---|---|---|---|
| 30. Juni 2026 | Aug 5, 2026 | $-0.21 | $-0.26 | 18.1% |
| 31. März 2026 | Mai 12, 2026 | $-0.37 | $-0.33 | -12.6% |
| 31. Dezember 2025 | $-0.29 | $-0.39 | 25.5% | |
| 30. September 2025 | $-0.41 | $-0.56 | 26.2% | |
| 30. Juni 2025 | $-1.05 | $-1.06 | 1.0% | |
| 31. März 2025 | $-1.31 | $-1.17 | -12.0% |
Vollständige Fundamentaldaten Alle Kennzahlen nach Jahr — Gewinn- und Verlustrechnung, Bilanz, Cashflow
Gewinn- und Verlustrechnung
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | $175M | $55M | $682.0K | $0 | |
| Cost of Revenue | $23M | $8M | $167.0K | $0 | |
| Gross Profit | $153M | $47M | $515.0K | $0 | |
| R&D Expense | $33M | $34M | $50M | $71M | |
| SG&A Expense | $280M | $291M | $118M | $101M | |
| Operating Expenses | $312M | $325M | $168M | $172M | |
| Operating Income | $-160M | $-277M | $-167M | $-172M | |
| Interest Expense | · | · | $42M | $27M | |
| Interest Income | $7M | $15M | $8M | $2M | |
| Other Non-op | $-190.0K | $-8.0K | $-188.0K | $-110.0K | |
| Pretax Income | $-221M | $-334M | · | · | |
| Income Tax | $0 | $0 | $0 | $0 | |
| Net Income | $-221M | $-334M | $-202M | $-198M | |
| EPS (Basic) | $-3.03 | $-5.29 | $-3.93 | $-5.05 | |
| EPS (Diluted) | $-3.03 | $-5.29 | $-3.93 | $-5.05 | |
| Shares (Basic) | 72,918,764 | 63,176,210 | 51,289,092 | 39,118,215 | |
| Shares (Diluted) | 72,918,764 | 63,176,210 | 51,289,092 | 39,118,215 | |
| EBITDA | $-159M | $-277M | $-167M | $-172M |
Bilanz
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Cash & Equivalents | $130M | $297M | $381M | $155M | |
| Receivables | $78M | $39M | $2M | $0 | |
| Inventory | $6M | $3M | $1M | $0 | |
| Prepaid Expense | $15M | $21M | $13M | $5M | |
| Current Assets | $229M | $360M | $397M | $161M | |
| PP&E (Net) | $1M | $1M | $2M | $1M | |
| PP&E (Gross) | $5M | $4M | $4M | $3M | |
| Accum. Depreciation | $3M | $3M | $2M | $1M | |
| Other Non-current Assets | $3M | $2M | $2M | $299.0K | |
| Total Assets | $259M | $378M | $414M | $165M | |
| Accounts Payable | $5M | $11M | $13M | $10M | |
| Accrued Liabilities | $90M | $53M | $17M | $15M | |
| Current Liabilities | $132M | $86M | $39M | $26M | |
| Capital Leases | $2M | · | $462.0K | $1M | |
| Other Non-current Liabilities | $4M | $12M | $10M | $8M | |
| Total Liabilities | $697M | $632M | $487M | $240M | |
| Long-term Debt | $209M | $201M | $138M | $95M | |
| Total Debt | $209M | $201M | $138M | $95M | |
| Common Stock | $6.0K | $6.0K | $5.0K | $3.0K | |
| Retained Earnings | $-1.48B | $-1.26B | $-929M | $-727M | |
| Treasury Stock | $0 | $0 | $0 | $0 | |
| Stockholders' Equity | $-438M | $-254M | $-73M | $-75M | |
| Liabilities + Equity | $259M | $378M | $414M | $165M | |
| Shares Outstanding | 71,419,025 | 68,518,238 | 57,970,044 | 41,468,871 |
Cashflow
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| D&A | $633.0K | $795.0K | $575.0K | $620.0K | |
| Stock-based Comp | $29M | $24M | $45M | $24M | |
| Other Non-cash | $25M | $43M | $18M | $26M | |
| Operating Cash Flow | $-167M | $-267M | $-138M | $-147M | |
| CapEx | $229.0K | $135.0K | $2M | $1M | |
| Investing Cash Flow | $-229.0K | $-135.0K | $-2M | $-1M | |
| Debt Issued | $0 | $59M | $39M | $0 | |
| Net Debt Issued | $0 | $59M | $39M | · | |
| Stock Issued | · | · | $14M | · | |
| Financing Cash Flow | $-288.0K | $183M | $368M | $120M | |
| Net Change in Cash | $-167M | $-84M | $228M | $-28M | |
| Free Cash Flow | $-167M | $-267M | $-139M | $-148M |
Rentabilität
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Gross Margin | 87.1% | 85.6% | 75.5% | · | |
| Operating Margin | -91.4% | -502.2% | -24532.5% | · | |
| Net Margin | -126.4% | -605.1% | -29558.9% | · | |
| Pretax Margin | -126.4% | · | · | · | |
| EBITDA Margin | -91.0% | -500.8% | -24448.2% | · | |
| ROA | -69.4% | -84.4% | -69.7% | -111.6% | |
| ROE | 52.4% | 151.7% | 445.4% | 390.6% | |
| ROIC | 69.8% | · | · | · |
Liquidität & Solvenz
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Current Ratio | 1.7 | 4.2 | 10.2 | 6.1 | |
| Quick Ratio | 1.6 | 3.9 | 9.9 | 5.9 | |
| Debt / Equity | -0.5 | -0.8 | -1.9 | -1.3 | |
| LT Debt / Equity | -0.5 | -0.8 | -1.9 | -1.3 | |
| Interest Coverage | · | · | -4.0 | -6.3 |
Effizienz
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Asset Turnover | 0.5 | 0.1 | 0.0 | · | |
| Inventory Turnover | 5.2 | 3.6 | 0.3 | · | |
| Receivables Turnover | 3.0 | 2.7 | 0.8 | · |
Pro Aktie
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Book Value / Share | $-6.14 | $-4.37 | $-1.26 | $-1.80 | |
| Revenue / Share | $2.40 | $0.87 | $0.01 | · | |
| Cash Flow / Share | $-2.29 | $-4.22 | $-2.68 | $-3.75 | |
| Cash / Share | $1.82 | $5.13 | $6.58 | $3.75 | |
| EPS (TTM) | $-3.03 | $-5.29 | $-3.93 | $-5.05 |
Wachstumsraten
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue YoY | 216.9% | 8001.5% | · | · |
Bewertung (TTM)
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue TTM | $175M | $55M | $682.0K | $0 | |
| Net Income TTM | $-221M | $-334M | $-202M | $-198M | |
| Market Cap | $1.18B | $471M | $529M | $465M | |
| Enterprise Value | $1.26B | $375M | $286M | $405M | |
| P/E | -5.5 | -1.5 | -2.3 | -2.2 | |
| P/S | 6.8 | 8.5 | 776.1 | · | |
| P/B | -2.7 | -1.9 | -7.3 | -6.2 | |
| P / Cash Flow | -7.1 | -1.8 | -3.8 | -3.2 | |
| P / FCF | -7.1 | -1.8 | -3.8 | -3.2 | |
| EV / EBITDA | -7.9 | -1.4 | -1.7 | -2.4 | |
| EV / FCF | -7.6 | -1.4 | -2.1 | -2.7 | |
| EV / Revenue | 7.2 | 6.8 | 418.9 | · | |
| Earnings Yield | -18.3% | -65.1% | -43.0% | -45.0% |
Gewinn- und Verlustrechnung
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $74M | $58M | $58M | $50M | $40M | $29M | $30M | $16M | $7M | $2M | $682.0K | $0 | $0 | $0 | |
| Cost of Revenue | $15M | $12M | $8M | $6M | $5M | $4M | $4M | $2M | $1M | $426.0K | $167.0K | $0 | $0 | $0 | |
| Gross Profit | $59M | $46M | $50M | $43M | $34M | $25M | $26M | $14M | $6M | $1M | $515.0K | $0 | $0 | $0 | |
| R&D Expense | $8M | $8M | $7M | $7M | $9M | $9M | $9M | $9M | $7M | $9M | $13M | $12M | $13M | $11M | |
| SG&A Expense | $55M | $54M | $48M | $52M | $85M | $94M | $77M | $76M | $76M | $62M | $57M | $23M | $19M | $19M | |
| Operating Expenses | $63M | $62M | $56M | $59M | $94M | $104M | $85M | $85M | $83M | $71M | $70M | $36M | $32M | $30M | |
| Operating Income | $-4M | $-15M | $-6M | $-15M | $-60M | $-79M | $-59M | $-71M | $-77M | $-70M | $-70M | $-36M | $-32M | $-30M | |
| Interest Expense | · | · | · | · | · | · | · | · | $18M | $17M | · | $10M | $10M | $9M | |
| Interest Income | $2M | $2M | $1M | $1M | $2M | $3M | $4M | $4M | $4M | $4M | $3M | $3M | $348.0K | $1M | |
| Other Non-op | $-24.0K | $-831.0K | $-6.0K | $-7.0K | $-155.0K | $-22.0K | $49.0K | $-8.0K | $-6.0K | $-43.0K | $-14.0K | $-197.0K | $3.0K | $20.0K | |
| Net Income | $-18M | $-30M | $-21M | $-30M | $-76M | $-94M | $-74M | $-86M | $-91M | $-83M | $-80M | $-43M | $-41M | $-38M | |
| EPS (Basic) | $-0.21 | $-0.37 | $-0.26 | $-0.41 | $-1.05 | $-1.31 | $-0.99 | $-1.32 | $-1.56 | $-1.42 | $-1.44 | $-0.76 | $-0.84 | $-0.89 | |
| EPS (Diluted) | $-0.21 | $-0.37 | $-0.26 | $-0.41 | $-1.05 | $-1.31 | $-0.99 | $-1.32 | $-1.56 | $-1.42 | $-1.44 | $-0.76 | $-0.84 | $-0.89 | |
| Shares (Basic) | 83,747,104 | 82,050,618 | · | 73,396,435 | 72,466,203 | 71,969,411 | · | 64,627,847 | 58,558,145 | 58,371,480 | · | 56,782,379 | 48,500,516 | 42,354,520 | |
| Shares (Diluted) | 83,747,104 | 82,050,618 | · | 73,396,435 | 72,466,203 | 71,969,411 | · | 64,627,847 | 58,558,145 | 58,371,480 | · | 56,782,379 | 48,500,516 | 42,354,520 | |
| EBITDA | $-4M | $-15M | · | $-15M | $-60M | $-79M | · | $-71M | $-77M | $-70M | · | $-36M | $-32M | $-30M |
Bilanz
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $182M | $181M | $130M | $135M | $150M | $212M | $297M | $335M | $276M | $322M | $381M | $214M | $249M | $130M | |
| Receivables | $97M | $81M | $78M | $56M | $51M | $36M | $39M | $21M | $11M | $4M | $2M | · | · | · | |
| Inventory | $8M | $7M | $6M | $4M | $3M | $3M | $3M | $3M | $2M | $1M | $1M | $111.0K | $111.0K | · | |
| Prepaid Expense | $8M | $8M | $15M | $13M | $15M | $13M | $21M | $15M | $15M | $13M | $13M | $13M | $9M | $10M | |
| Current Assets | $296M | $277M | $229M | $208M | $219M | $265M | $360M | $374M | $305M | $340M | $397M | $227M | $258M | $140M | |
| PP&E (Net) | $971.0K | $1M | $1M | $1M | $1M | $1M | $1M | $2M | $2M | $2M | $2M | $2M | $1M | $1M | |
| PP&E (Gross) | · | · | $5M | · | · | · | $4M | $4M | $4M | $4M | $4M | $4M | $3M | $3M | |
| Accum. Depreciation | · | · | $3M | · | · | · | $3M | $3M | $2M | $2M | $2M | $2M | $2M | $2M | |
| Other Non-current Assets | $3M | $3M | $3M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $4M | $4M | $299.0K | |
| Total Assets | $327M | $305M | $259M | $240M | $250M | $294M | $378M | $387M | $319M | $356M | $414M | $237M | $265M | $144M | |
| Accounts Payable | $5M | $6M | $5M | $1M | $4M | $12M | $11M | $7M | $8M | $8M | $13M | $6M | $4M | $5M | |
| Accrued Liabilities | $109M | $83M | $90M | $65M | $64M | $43M | $53M | $36M | $27M | $17M | $17M | $13M | $15M | $8M | |
| Current Liabilities | $154M | $125M | $132M | $93M | $92M | $74M | $86M | $65M | $47M | $43M | $39M | $24M | $22M | $14M | |
| Capital Leases | $2M | $2M | $2M | $2M | $589.0K | $0 | · | $0 | $133.0K | $292.0K | $462.0K | $628.0K | $789.0K | $945.0K | |
| Other Non-current Liabilities | $4M | $4M | $4M | $12M | $12M | $12M | $12M | $11M | $10M | $10M | $10M | $8M | $8M | $8M | |
| Total Liabilities | $671M | $642M | $697M | $663M | $656M | $633M | $632M | $574M | $553M | $505M | $487M | $255M | $247M | $234M | |
| Long-term Debt | $165M | $164M | $209M | $207M | $205M | $203M | $201M | $176M | $174M | $149M | $138M | $99M | $98M | $97M | |
| Total Debt | $165M | $164M | · | $207M | $205M | $203M | · | $176M | $174M | $149M | · | $99M | $98M | $97M | |
| Common Stock | $8.0K | $7.0K | $6.0K | $6.0K | $6.0K | $6.0K | $6.0K | $6.0K | $5.0K | $5.0K | $5.0K | $5.0K | $5.0K | $4.0K | |
| Retained Earnings | $-1.53B | $-1.51B | $-1.48B | $-1.46B | $-1.43B | $-1.36B | $-1.26B | $-1.19B | $-1.10B | $-1.01B | $-929M | $-849M | $-806M | $-765M | |
| Treasury Stock | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | |
| Stockholders' Equity | $-344M | $-337M | $-438M | $-423M | $-406M | $-338M | $-254M | $-187M | $-234M | $-149M | $-73M | $-18M | $18M | $-90M | |
| Liabilities + Equity | $327M | $305M | $259M | $240M | $250M | $294M | $378M | $387M | $319M | $356M | $414M | $237M | $265M | $144M | |
| Shares Outstanding | 80,070,048 | 79,442,367 | 71,419,025 | 71,043,149 | 70,104,419 | 69,638,070 | 68,518,238 | 68,323,938 | 58,601,025 | 58,524,101 | 57,970,044 | 56,809,085 | 56,639,085 | 43,571,140 |
Cashflow
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $114.0K | $110.0K | $128.0K | $156.0K | $172.0K | $177.0K | $193.0K | $191.0K | $197.0K | $214.0K | $185.0K | $121.0K | $123.0K | $146.0K | |
| Stock-based Comp | $7M | $6M | $6M | $9M | $8M | $6M | $7M | $6M | $6M | $6M | $25M | $6M | $7M | $7M | |
| Other Non-cash | · | $9M | · | · | · | $4M | · | · | · | $8M | · | · | · | $-9M | |
| Operating Cash Flow | $-2M | $-16M | $-5M | $-14M | $-63M | $-85M | $-63M | $-64M | $-71M | $-69M | $-44M | $-32M | $-22M | $-40M | |
| CapEx | $44.0K | $61.0K | $87.0K | $27.0K | $97.0K | $18.0K | $5.0K | $44.0K | $46.0K | $40.0K | $475.0K | $939.0K | $6.0K | $214.0K | |
| Investing Cash Flow | $-44.0K | $-61.0K | $-87.0K | $-27.0K | $-97.0K | $-18.0K | $-5.0K | $-44.0K | $-46.0K | $-40.0K | $-475.0K | $-939.0K | $-6.0K | $-214.0K | |
| Debt Issued | $0 | $173M | $0 | $0 | $0 | $0 | $25M | $0 | $25M | $10M | $39M | $0 | $0 | $0 | |
| Net Debt Issued | · | $-56M | · | · | · | $0 | · | · | · | $10M | · | · | · | · | |
| Stock Issued | · | · | · | · | · | · | · | · | · | · | $0 | $0 | · | · | |
| Financing Cash Flow | $4M | $67M | $-97.0K | $-271.0K | $80.0K | $0 | $26M | $122M | $25M | $10M | $212M | $13.0K | $142M | $14M | |
| Net Change in Cash | $2M | $51M | $-5M | $-14M | $-63M | $-85M | $-37M | $58M | $-46M | $-59M | $168M | $-33M | $119M | $-26M | |
| Free Cash Flow | · | $-16M | · | · | · | $-85M | · | · | · | $-69M | · | · | · | $-40M |
Rentabilität
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 79.7% | 79.4% | · | 87.5% | 87.2% | 86.9% | · | 85.6% | 81.2% | 77.7% | · | · | · | · | |
| Operating Margin | -5.3% | -26.6% | · | -30.9% | -151.7% | -276.5% | · | -433.0% | -1055.4% | -3658.7% | · | · | · | · | |
| Net Margin | -23.7% | -52.1% | · | -60.6% | -191.9% | -330.7% | · | -523.3% | -1248.6% | -4333.3% | · | · | · | · | |
| EBITDA Margin | -5.3% | -26.4% | · | -30.9% | -151.7% | -275.9% | · | -433.0% | -1055.4% | -3647.5% | · | · | · | · | |
| ROA | -6.1% | -10.1% | · | -9.6% | -26.6% | -29.0% | · | -27.4% | -31.3% | -33.1% | · | -19.7% | -17.1% | -25.8% | |
| ROE | 4.7% | 9.0% | · | 9.8% | 23.7% | 38.7% | · | 83.5% | 84.6% | 69.4% | · | 195.7% | -772.9% | 145.0% |
Liquidität & Solvenz
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 1.9 | 2.2 | · | 2.2 | 2.4 | 3.6 | · | 5.7 | 6.5 | 7.8 | · | 9.5 | 12.0 | 9.7 | |
| Quick Ratio | 1.8 | 2.1 | · | 2.1 | 2.2 | 3.4 | · | 5.4 | 6.1 | 7.5 | · | 8.9 | 11.6 | 9.0 | |
| Debt / Equity | -0.5 | -0.5 | · | -0.5 | -0.5 | -0.6 | · | -0.9 | -0.7 | -1.0 | · | -5.6 | 5.6 | -1.1 | |
| LT Debt / Equity | -0.5 | -0.5 | · | -0.5 | -0.5 | -0.6 | · | -0.9 | -0.7 | -1.0 | · | -5.6 | 5.6 | -1.1 | |
| Interest Coverage | · | · | · | · | · | · | · | · | -4.4 | -4.1 | · | -3.5 | -3.3 | -3.3 |
Effizienz
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.3 | 0.2 | · | 0.2 | 0.1 | 0.1 | · | 0.1 | 0.0 | 0.0 | · | · | · | · | |
| Inventory Turnover | 2.7 | 2.5 | · | 1.8 | 1.8 | 1.6 | · | 1.5 | 1.2 | 0.6 | · | · | · | · | |
| Receivables Turnover | 1.0 | 1.0 | · | 1.3 | 1.3 | 1.4 | · | 1.6 | 1.3 | 1.0 | · | · | · | · |
Pro Aktie
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Book Value / Share | $-4.30 | $-4.24 | · | $-5.95 | $-5.79 | $-4.86 | · | $-2.74 | $-3.99 | $-2.54 | · | $-0.31 | $0.31 | $-2.07 | |
| Revenue / Share | $0.89 | $0.71 | · | $0.67 | $0.55 | $0.40 | · | $0.25 | $0.13 | $0.03 | · | · | · | · | |
| Cash Flow / Share | · | $-0.19 | · | · | · | $-1.18 | · | · | · | $-1.18 | · | · | · | $-0.94 | |
| Cash / Share | $2.28 | $2.28 | · | $1.90 | $2.13 | $3.05 | · | $4.90 | $4.71 | $5.51 | · | $3.76 | $4.39 | $2.97 | |
| EPS (TTM) | $-1.25 | $-2.09 | · | $-3.76 | $-4.67 | $-5.18 | · | $-5.74 | $-5.18 | $-4.46 | · | $-3.82 | $-4.38 | $-4.87 |
Bewertung (TTM)
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $240M | $205M | · | $147M | $114M | $82M | · | $26M | $10M | $3M | · | · | · | · | |
| Net Income TTM | $-99M | $-157M | · | $-275M | $-330M | $-346M | · | $-339M | $-297M | $-247M | · | $-177M | $-185M | $-195M | |
| Market Cap | $869M | $883M | · | $836M | $672M | $437M | · | $1.24B | $604M | $622M | · | $589M | $811M | $311M | |
| Enterprise Value | $851M | $865M | · | $908M | $728M | $428M | · | $1.08B | $502M | $448M | · | $475M | $660M | $278M | |
| P/E | -8.7 | -5.3 | · | -3.1 | -2.1 | -1.2 | · | -3.1 | -2.0 | -2.4 | · | -2.7 | -3.3 | -1.5 | |
| P/S | 3.6 | 4.3 | · | 5.7 | 5.9 | 5.3 | · | 47.0 | 60.9 | 239.6 | · | · | · | · | |
| P/B | -2.5 | -2.6 | · | -2.0 | -1.7 | -1.3 | · | -6.6 | -2.6 | -4.2 | · | -33.1 | 46.1 | -3.4 | |
| P / Tangible Book | · | · | · | · | · | · | · | · | · | · | · | · | 46.1 | · | |
| P / Cash Flow | · | -56.4 | · | · | · | -5.1 | · | · | · | -9.0 | · | · | · | -7.8 | |
| EV / Revenue | 3.6 | 4.2 | · | 6.2 | 6.4 | 5.2 | · | 41.0 | 50.6 | 172.8 | · | · | · | · | |
| Earnings Yield | -11.5% | -18.8% | · | -31.9% | -48.7% | -82.6% | · | -31.8% | -50.3% | -42.0% | · | -36.8% | -30.6% | -68.2% |
Aktuellster Zeitraum links · fehlende Werte werden als · angezeigt
Finanzberichte Gewinn- und Verlustrechnung, Bilanz, Cashflow — jährlich, letzte 5 Jahre
| Kennzahl | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Umsatz | $175M | $55M | $682.0K | $0 | · |
| Bruttogewinnmarge % | 87.1% | 85.6% | 75.5% | · | · |
| Betriebsgewinnmarge % | -91.4% | -502.2% | -24532.5% | · | · |
| Nettoergebnis | $-221M | $-334M | $-202M | $-198M | $-144M |
| Verwässerte EPS | $-3.03 | $-5.29 | $-3.93 | $-5.05 | $-3.89 |
| Kennzahl | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Fremdkapital / Eigenkapital | -0.5 | -0.8 | -1.9 | -1.3 | 1.2 |
| Liquiditätsgrad | 1.7 | 4.2 | 10.2 | 6.1 | 9.9 |
| Quick Ratio | 1.6 | 3.9 | 9.9 | 5.9 | 9.7 |
| Kennzahl | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Freier Cashflow | $-167M | $-267M | $-139M | $-148M | $-149M |
Institutionelle Eigentümer (13F) 176 Einreicher · $818.8M gesamt · Stand 30. Juni 2026
Institutionen, die diese Aktie in ihrer vierteljährlichen SEC-Formular 13F melden. Nur Long-Positionen; ein einzelner Einreicher kann für separate Optionsscheine zweimal erscheinen. Große gegenläufige Put/Call-Positionen spiegeln typischerweise Market-Making oder abgesicherte Bestände wider, nicht die gerichtete Überzeugung.
Inhaber
176
Gehaltener Wert
$818.8M
Neue Positionen
26
Geschlossene Positionen
31
Institutionelle Aktivität — Q2 2026 vs. Vorquartal
| Neue Positionen | Geschlossene Positionen | Erhöht | Abgenommen | Nettoveränderung der Aktien |
|---|---|---|---|---|
| 26 (-13 vs. Vorquartal) | 31 (-4 vs. Vorquartal) | 59 (-16 vs. Vorquartal) | 52 (+12 vs. Vorquartal) | +5.7M |
Verglichen mit Q1 2026. SEC-Formular 13F-Einreichungen sind innerhalb von 45 Tagen nach Quartalsende fällig, zuzüglich einer kurzen Pufferzeit für verspätete Einreicher — Quartale, die noch in diesem Fenster liegen, werden zugunsten des letzten vollständig berichteten Paares übersprungen.
| Institution | Wert | Aktien | % der verfolgten 13F | Typ |
|---|---|---|---|---|
| Frazier Life Sciences Management, L.P. | $135.261.406 | 12.466.489 | 16,52% | Aktien |
| Medicxi Ventures Management (Jersey) Ltd | $80.990.606 | 7.464.572 | 9,89% | Aktien |
| VANGUARD GROUP INC | $52.709.931 | 3.177.211 | 6,44% | Aktien |
| BlackRock, Inc. | $49.097.648 | 4.525.129 | 6,00% | Aktien |
| Invesco Ltd. | $43.722.581 | 4.029.731 | 5,34% | Aktien |
| Carlyle Group Inc. | $37.940.367 | 3.496.808 | 4,63% | Aktien |
| MILLENNIUM MANAGEMENT LLC | $36.627.799 | 3.375.834 | 4,47% | Aktien |
| VANGUARD CAPITAL MANAGEMENT LLC | $28.827.842 | 2.656.944 | 3,52% | Aktien |
| FRANKLIN RESOURCES INC | $21.383.482 | 1.970.828 | 2,61% | Aktien |
| NEA Management Company, LLC | $21.267.834 | 1.960.169 | 2,60% | Aktien |
| 683 Capital Management, LLC | $20.072.501 | 1.850.000 | 2,45% | Aktien |
| GOLDMAN SACHS GROUP INC | $19.291.647 | 1.778.032 | 2,36% | Aktien |
| STATE STREET CORP | $17.211.605 | 1.586.323 | 2,10% | Aktien |
| Catalys Pacific, LLC | $16.208.316 | 1.493.854 | 1,98% | Aktien |
| NOMURA ASSET MANAGEMENT INTERNATIONAL INC. | $15.871.000 | 1.462.738 | 1,94% | Aktien |
| WASATCH ADVISORS LP | $14.897.577 | 1.340.916 | 1,82% | Aktien |
| GEODE CAPITAL MANAGEMENT, LLC | $14.277.589 | 1.315.687 | 1,74% | Aktien |
| Ensign Peak Advisors, Inc | $11.413.256 | 1.051.913 | 1,39% | Aktien |
| Propel Bio Management, LLC | $11.396.384 | 1.050.358 | 1,39% | Aktien |
| Point72 Asset Management, L.P. | $11.090.794 | 1.022.193 | 1,35% | Aktien |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $8.643.446 | 796.631 | 1,06% | Aktien |
| SummitTX Capital, L.P. | $8.566.618 | 789.550 | 1,05% | Aktien |
| HSBC HOLDINGS PLC | $7.701.936 | 709.695 | 0,94% | Aktien |
| MARSHALL WACE, LLP | $7.227.078 | 666.090 | 0,88% | Aktien |
| EcoR1 Capital, LLC | $6.781.250 | 625.000 | 0,83% | Aktien |
| PERCEPTIVE ADVISORS LLC | $5.772.200 | 532.000 | 0,70% | Aktien |
| TWO SIGMA INVESTMENTS, LP | $5.631.975 | 519.076 | 0,69% | Aktien |
| CITADEL ADVISORS LLC | $5.216.680 | 480.800 | 0,64% | Kaufoption |
| NORTHERN TRUST CORP | $4.972.565 | 458.301 | 0,61% | Aktien |
| StepStone Group LP | $4.689.364 | 422.085 | 0,57% | Aktien |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | $4.547.170 | 419.094 | 0,56% | Aktien |
| Woodline Partners LP | $4.004.214 | 369.052 | 0,49% | Aktien |
| VANGUARD FIDUCIARY TRUST CO | $3.847.117 | 354.573 | 0,47% | Aktien |
| AMERIPRISE FINANCIAL INC | $3.189.673 | 293.979 | 0,39% | Aktien |
| JPMORGAN CHASE & CO | $2.991.978 | 275.251 | 0,37% | Aktien |
| Simplify Asset Management Inc. | $2.704.547 | 249.267 | 0,33% | Aktien |
| RENAISSANCE TECHNOLOGIES LLC | $2.456.440 | 226.400 | 0,30% | Aktien |
| JANE STREET GROUP, LLC | $2.307.860 | 212.706 | 0,28% | Aktien |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $2.281.755 | 210.300 | 0,28% | Kaufoption |
| UBS Group AG | $2.219.618 | 204.573 | 0,27% | Aktien |
| NewEdge Advisors, LLC | $2.212.988 | 203.962 | 0,27% | Aktien |
| Avidity Partners Management LP | $2.170.000 | 200.000 | 0,27% | Aktien |
| MORGAN STANLEY | $2.169.013 | 199.909 | 0,26% | Aktien |
| Jump Financial, LLC | $2.081.746 | 191.866 | 0,25% | Aktien |
| Opaleye Management Inc. | $2.013.641 | 185.589 | 0,25% | Aktien |
| CITADEL ADVISORS LLC | $2.006.176 | 184.901 | 0,25% | Aktien |
| Trexquant Investment LP | $1.886.641 | 173.884 | 0,23% | Aktien |
| Jones Hill Capital LP | $1.752.123 | 161.486 | 0,21% | Aktien |
| Bank of New York Mellon Corp | $1.652.595 | 152.313 | 0,20% | Aktien |
| WELLS FARGO & COMPANY/MN | $1.649.221 | 152.002 | 0,20% | Aktien |
Aktivisten & 5%+-Eigentümer 5 Beteiligungen
Investoren mit SEC Schedule 13D — wirtschaftliches Eigentum über 5% mit der Absicht, Einfluss auf den Emittenten zu nehmen (aktivistische Beteiligungen, Board-Kampagnen, M&A). Jede Zeile zeigt den zuletzt bekannten Stand der Position dieses Melders.
| Anmelder | Eingereicht | Beteiligung | Status | Zweck | Einreichung |
|---|---|---|---|---|---|
| Frazier Life Sciences Public Fund, L.P., FHMLSP, L.P., FHMLSP, L.L.C., Frazier Life Sciences X, L.P., FHMLS X, L.P., FHMLS X, L.L.C., Frazier Life Sciences XI, L.P., FHMLS XI, L.P., FHMLS XI, L.L.C., Frazier Life Sciences IX, L.P., FHMLS IX, L.P., FHMLS IX, L.L.C., Frazier Life Sciences XII, L.P., FHMLS XII, L.P., FHMLS XII, L.L.C., James N. Topper, Patrick J. Heron ×3 Einreichungen | 4. November 2025 | 8,60% | Änderung | · | SEC |
| Frazier Life Sciences IX, L.P., FHMLS IX, L.P., FHMLS IX, L.L.C., Frazier Life Sciences Public Fund, L.P., FHMLSP, L.P., FHMLSP, L.L.C., Frazier Life Sciences Public Overage Fund, L.P., FHMLSP Overage, L.P., FHMLSP Overage, L.L.C., Frazier Life Sciences XI, L.P., FHMLS XI, L.P., FHMLS XI, L.L.C., James N. Topper, Patrick J. Heron, Albert Cha, James Brush, Daniel Estes ×8 Einreichungen | 22. August 2024 | · | Erste Einreichung | Passive Anlage | SEC |
| Takeda Pharmaceutical Company Limited ×3 Einreichungen | 10. April 2024 | · | Erste Einreichung | · | SEC |
| Frazier Life Sciences IX, L.P ., FHMLS IX, L.P., FHMLS IX, L.L.C., Frazier Life Sciences Public Fund, L.P., FHMLSP, L.P., FHMLSP, L.L.C., Frazier Life Sciences Public Overage Fund, L.P., FHMLSP Overage, L.P., FHMLSP Overage, L.L.C., Frazier Life Sciences XI, L.P., FHMLS XI, L.P., FHMLS XI, L.L.C., James N. Topper, Patrick J. Heron, Albert Cha, James Brush, Daniel Estes | 26. Mai 2023 | · | Erste Einreichung | Passive Anlage | SEC |
| S.S. OR ×5 Einreichungen | 12. November 2021 | · | Erste Einreichung | · | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
Unternehmensinsider 20 Insider · 9 Führungskräfte · 12 Direktoren
| Insider | Rolle | Letzte Aktivität | Gehaltene Aktien | Käufe 12m | Verkäufe 12m | Netto 12m |
|---|---|---|---|---|---|---|
| Steven L Basta | President and CEO | 10. Februar 2026 F | 373.315 | 0 | 0 | $0 |
| Molly Henderson | CFO and CBO | 7. April 2025 S | 89.868 | 0 | 0 | $0 |
| Todd P. Branning | Chief Financial Officer | 28. Januar 2021 A | · | 0 | 0 | $0 |
| Terrie Curran | President and Chief Executive | 27. Februar 2025 A | 360.465 | 0 | 0 | $0 |
| Azmi Nabulsi | Chief Operating Officer | 27. Februar 2025 A | 312.590 | 0 | 0 | $0 |
| Robert Charles Breedlove | Principal Accounting Officer | 3. September 2026 F | 59.465 | 0 | 1 | $-7.079 |
| Anne Marie Cook | Chief Legal Off. & Corp. Sec. | 10. Februar 2026 F | 88.660 | 0 | 0 | $0 |
| Sanjeev Narula | Chief Financial & Bus. Officer | 2. Januar 2026 A | 226.715 | 0 | 0 | $0 |
| Anthony J. Guzzo | VP, Chief Accounting Officer | 19. Januar 2022 A | 8.399 | 0 | 0 | $0 |
| Asit Parikh | Direktor | 22. Mai 2026 G | 148.500 | 0 | 0 | $0 |
| Mark Stenhouse | Direktor | 19. Mai 2026 A | 54.122 | 0 | 0 | $0 |
| Theodore R Schroeder | Direktor | 19. Mai 2026 A | 45.122 | 0 | 0 | $0 |
| James N. Topper | Direktor | 19. Mai 2026 A | 66.718 | 0 | 0 | $0 |
| Frank Karbe | Direktor | 19. Mai 2026 A | 91.622 | 0 | 0 | $0 |
| Michael F Cola | Direktor | 19. Mai 2026 A | 63.920 | 0 | 0 | $0 |
| Heidi Kunz | Direktor | 19. Mai 2026 A | 54.122 | 0 | 0 | $0 |
| David A Socks | Direktor | 23. Mai 2024 A | 19.500 | 0 | 0 | $0 |
| Tadataka Yamada | Direktor | 21. Mai 2021 A | · | 0 | 0 | $0 |
| Jonathan S. Edwards | Direktor | 29. Oktober 2019 C | 47.984 | 0 | 0 | $0 |
| Takeda Pharmaceutical Company Limited | · | 24. Januar 2024 S | 3.755.583 | 0 | 0 | $0 |
Insider aus SEC-Einreichungen Form 3/4/5; Netto = nur P/S aus offenen Märkten
ETF-Besitz Gehalten von 24 ETFs
Gewichtung spiegelt nur direkte Aktienbestände (N-PORT) wider; gehebelte oder derivatbasierte Fonds können zusätzliche Swap-Exposure halten, die hier nicht angezeigt wird.
| Fonds | Gewicht | Anteile | Stand | Quelle |
|---|---|---|---|---|
| BBP · ETFis Series Trust I | 1,16% | 130.873 NS | 31. Juli 2026 | N-PORT |
| PILL · Direxion Shares ETF Trust | 0,64% | 15.083 NS | 31. Juli 2026 | N-PORT |
| IWC · iShares Trust | 0,10% | 167.720 SH | 11. September 2026 | Täglich |
| IHE · iShares Trust | 0,10% | 187.890 SH | 11. September 2026 | Täglich |
| VFMO · VANGUARD WELLINGTON FUND | 0,04% | 78.352 SH | 19. August 2026 | Täglich |
| IBBQ · Invesco Exchange-Traded Fund Trust … | 0,04% | 5.742 SH | 1. Oktober 2026 | Täglich |
| IBB · iShares Trust | 0,04% | 439.273 SH | 11. September 2026 | Täglich |
| VTWO · VANGUARD SCOTTSDALE FUNDS | 0,02% | 283.184 SH | 19. August 2026 | Täglich |
| VTWV · VANGUARD SCOTTSDALE FUNDS | 0,02% | 30.521 SH | 19. August 2026 | Täglich |
| ISCG · iShares Trust | 0,02% | 18.633 SH | 11. September 2026 | Täglich |
| RSSL · Global X Funds | 0,01% | 23.493 NS | 31. Juli 2026 | N-PORT |
| IWM · iShares Trust | 0,01% | 1.255.887 SH | 11. September 2026 | Täglich |
| VXF · VANGUARD INDEX FUNDS | 0,01% | 586.438 SH | 19. August 2026 | Täglich |
| VTWG · VANGUARD SCOTTSDALE FUNDS | 0,01% | 15.003 SH | 19. August 2026 | Täglich |
| VHT · VANGUARD WORLD FUND | 0,01% | 148.237 SH | 19. August 2026 | Täglich |
| IWO · iShares Trust | 0,01% | 132.821 SH | 11. September 2026 | Täglich |
| FHLC · FIDELITY COVINGTON TRUST | 0,01% | 22.619 NS | 31. Juli 2026 | N-PORT |
| WSML · iShares Trust | 0,00% | 2.597 SH | 11. September 2026 | Täglich |
| ITOT · iShares Trust | 0,00% | 79.252 SH | 11. September 2026 | Täglich |
| IWV · iShares Trust | 0,00% | 9.388 SH | 3. September 2026 | Täglich |
| VTI · VANGUARD INDEX FUNDS | 0,00% | 2.007.668 SH | 19. August 2026 | Täglich |
| VTHR · VANGUARD SCOTTSDALE FUNDS | 0,00% | 3.478 SH | 19. August 2026 | Täglich |
| IWN · iShares Trust | · | 330.692 SH | 11. September 2026 | Täglich |
| ISCB · iShares Trust | · | 2.641 SH | 11. September 2026 | Täglich |
PHAT Analysten-Konsens Bullische und bärische Analystenmeinungen, 12-Monats-Kursziel, Aufwärtspotenzial
Bewertung · 17 Analysten
KAUF
Median-Ziel
$21.00
+203,5%
6 35,3%
Starker Kauf
9 52,9%
Kauf
2 11,8%
Halten
0 0,0%
Verkauf
0 0,0%
Starker Verkauf
12-Monats-Kursziel
11 Analysten · 2026-09-29Mittelwert-Ziel $20.45 +195,6%
← Unter allen Zielen
Aktueller Preis $6.92
Tief$10.00
Mittelwert$20.45
Hoch$29.00
Peer-Vergleich (GICS-Subbranche) Wichtige Kennzahlen im Vergleich zu Branchenkollegen
FY-Basis, Kurse zum Schlusskurs am Ende des letzten Geschäftsjahres jedes Unternehmens.
| Ticker | Marktkapitalisierung | P/E | Umsatz Vj. | Nettomarge | ROE | Bruttogewinnmarge |
|---|---|---|---|---|---|---|
| PHAT | $1.18B | -5.5 | 216.9% | -126.4% | 52.4% | 87.1% |
| COLL | $1.47B | 26.8 | 23.6% | 8.1% | 23.5% | 59.4% |
| ACRS | $363M | -5.7 | -58.2% | -829.6% | -55.3% | · |
| AQST | $788M | -8.3 | -22.6% | -188.1% | 157.7% | · |
| ZVRA | $509M | 6.6 | 350.9% | 78.2% | 61.2% | · |
| CRMD | $922M | 5.7 | 617.0% | 52.3% | 52.1% | 88.5% |
| CTNM | · | -5.3 | · | · | -27.7% | · |
| ARVN | $753M | -10.4 | -0.30% | -30.8% | -15.5% | · |
| EOLS | $432M | -8.3 | 11.6% | -17.4% | 247.3% | 66.3% |
Meine Kennzahlen Ihre persönliche Watchlist — ausgewählte Zeilen aus den vollständigen Fundamentaldaten
Wählen Sie die Kennzahlen, die für Sie wichtig sind — klicken Sie auf das + neben jeder Zeile in den vollständigen Fundamentaldaten oben.
Ihre Auswahl wird gespeichert und begleitet Sie über alle Ticker hinweg.
Quelle: SEC 10-Q eingereicht Jul 30, 2026